These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 8703657)

  • 1. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.
    Kivistö KT; Kroemer HK; Eichelbaum M
    Br J Clin Pharmacol; 1995 Dec; 40(6):523-30. PubMed ID: 8703657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions.
    Zhou-Pan XR; Sérée E; Zhou XJ; Placidi M; Maurel P; Barra Y; Rahmani R
    Cancer Res; 1993 Nov; 53(21):5121-6. PubMed ID: 8221648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
    Brandes LJ; Queen GM; LaBella FS
    Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.
    Marre F; Sanderink GJ; de Sousa G; Gaillard C; Martinet M; Rahmani R
    Cancer Res; 1996 Mar; 56(6):1296-302. PubMed ID: 8640817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
    Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
    Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 and anticancer drugs.
    Fujita K
    Curr Drug Metab; 2006 Jan; 7(1):23-37. PubMed ID: 16454691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between antiretrovirals and antineoplastic drug therapy.
    Antoniou T; Tseng AL
    Clin Pharmacokinet; 2005; 44(2):111-45. PubMed ID: 15656694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA.
    Jacobson PA; Green K; Birnbaum A; Remmel RP
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):461-7. PubMed ID: 12107550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation.
    Kumar GN; Walle UK; Walle T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1160-5. PubMed ID: 7908050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
    Rochat B
    Clin Pharmacokinet; 2005; 44(4):349-66. PubMed ID: 15828850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical approach for identifying drug interactions.
    Kamataki T; Yokoi T; Fujita K; Ando Y
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S50-3. PubMed ID: 9750029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
    van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.
    Kajita J; Kuwabara T; Kobayashi H; Kobayashi S
    Drug Metab Dispos; 2000 Sep; 28(9):1121-7. PubMed ID: 10950859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
    Butler AM; Murray M
    J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary effects on drug metabolism and transport.
    Harris RZ; Jang GR; Tsunoda S
    Clin Pharmacokinet; 2003; 42(13):1071-88. PubMed ID: 14531721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?
    Rochat B; Morsman JM; Murray GI; Figg WD; McLeod HL
    J Pharmacol Exp Ther; 2001 Feb; 296(2):537-41. PubMed ID: 11160641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.
    Gurley BJ; Gardner SF; Hubbard MA; Williams DK; Gentry WB; Cui Y; Ang CY
    Clin Pharmacol Ther; 2002 Sep; 72(3):276-87. PubMed ID: 12235448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
    Zhou SF; Xue CC; Yu XQ; Li C; Wang G
    Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4.
    Relling MV; Nemec J; Schuetz EG; Schuetz JD; Gonzalez FJ; Korzekwa KR
    Mol Pharmacol; 1994 Feb; 45(2):352-8. PubMed ID: 8114683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.